Chronic Obstructive Pulmonary Disease (COPD) Treatment Market by Drug Class (Bronchodilators (Beta 2-Agonists, Anticholinergics, Theophyllines), Phosphodiesterase Type 4 Inhibitors, Steroids, and Others), By Route of Administration (Oral and Inhalation), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2019 – 2026

  • Published On : May 2019 |
  • Pages : 178 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market – Insights

Chronic obstructive pulmonary disease (COPD) involves lung inflammation, causing obstruction of airflow from the lungs. It is a chronic disease and symptoms include difficulty in breathing, mucus formation, wheezing, and others. COPD is a progressive lung disease, which includes chronic bronchitis, emphysema, and refractory asthma. Prime causes behind occurrence of chronic obstructive pulmonary disease include smoking, air pollution, secondhand smoke, alpha-1 deficiency-related emphysema (rare form of COPD), and others. There are certain ways, by which complications can be prevented, as well as disease progression can be slowed down. These may include quitting smoking, adherence to the prescribed medication, and preventing associated co-morbidities such as flu, pneumonia, and others by vaccination against these diseases.

High incidence and prevalence of chronic obstructive pulmonary disease (COPD), coupled with awareness efforts carried out by individual organizations is expected to support global chronic obstructive pulmonary disease (COPD) treatment market growth over the forecast period

According to National Center for Biotechnology Information (NCBI), in 2016, chronic obstructive pulmonary disease (COPD) was the third leading cause of death, globally. Furthermore, according Global Burden of Disease Study, COPD was prevalent in over 300 million people globally in 2013. Moreover, according to the same source, in European adults over 40 years of age, the prevalence of COPD ranged from 15-20%, in 2016. Moreover, according to the World Health Organization (WHO), Global Burden of Disease Study reports prevalence of 251 million cases of COPD, globally, in 2016. Increasing prevalence is expected to support the global chronic obstructive pulmonary disease (COPD) treatment market growth over the forecast period. Organizations such as World Health Organization (WHO), COPD Foundation, American Thoracic Society, and Centers for Disease Control and Prevention (CDC) work towards raising COPD awareness in the population. National Institutes of Health (NIH) runs an initiative, ‘COPD Learn More Breathe Better’, and celebrates November as a national COPD awareness month. These factors are expected to support global chronic obstructive pulmonary disease (COPD) treatment market growth over the forecast period.

The global chronic obstructive pulmonary disease (COPD) treatment market size was valued at US$ 14,209.0 million in 2017, and is expected to witness a robust CAGR of 4.9% over the forecast period (2018–2026).

Figure 1. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), by Region, 2018 & 2026

chronic obstructive pulmonary disease copd market fig1

Source: Coherent Market Insights Analysis (2017)

Ongoing research and development and product launches is expected to support global chronic obstructive pulmonary disease (COPD) treatment market

Verona Pharma commenced a phase IIb clinical trial to assess nebulized ensifentrine (RPL554), in combination with a long-acting bronchodilator to treat moderate to severe COPD, in May 2019. Novartis AG launched Ultibro Breezhaler and Seebri Breezhaler in China for the treatment of COPD, in March 2019. Cipla launched Niveoli, beclomethasone-formoterol combination hydrofluoroalkane (HFA) inhaler for adults suffering from obstructive airway diseases (OAD) such as asthma and COPD, in April 2019. Moreover, manufacturers are also involved in improving overall COPD treatment paradigm by introducing medical devices, web-based applications, and other efforts to reduce the global burden of chronic obstructive pulmonary disease. For instance, Spire Health launched a study to develop new digital biomarkers that can predict exacerbations—and potentially hospitalizations—in patients with severe COPD, in May 2019. These factors are expected to support global chronic obstructive pulmonary disease (COPD) treatment market growth over the forecast period.

Figure 2. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share, by Distribution Channel, 2018 & 2026

chronic obstructive pulmonary disease copd treatment market fig2

However, development of new drugs is a challenging task and drug failures in clinical trials have affected growth of the market. For instance, asthma drug benralizumab failed to decrease annual COPD exacerbation rates for patients with moderate to very severe COPD, in May 2019. The Phase III, randomized, double-blind, placebo-controlled, parallel-group clinical trials GALATHEA and TERRANOVA evaluated the efficacy and safety of benralizumab for the prevention of exacerbations in patients with moderate to very severe COPD.

Some major players operating in the global chronic obstructive pulmonary disease (COPD) treatment market include AstraZeneca Plc, Orion Corporation, Mylan N.V., Boehringer Ingelheim, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Novartis AG, Sunovion Pharmaceuticals, Inc., and CHIESI Farmaceutici SpA

Chronic obstructive pulmonary disease (COPD) presents itself with mild, moderate, and severe symptoms. Treatment of chronic obstructive pulmonary disease (COPD) involves stepwise non-pharmacological and pharmacological interventions. Non-pharmacological interventions include risk reduction (smoking cessation) and preventing and treating co-morbidities (cardiovascular disease, anxiety, depression, and others). Pharmacological interventions include prescribing short acting bronchodilators, long acting bronchodilators, and others.

Market Dynamics

Factors such as awareness initiatives by organizations, increasing prevalence of COPD, and product launches is supporting the global chronic obstructive pulmonary disease (COPD) treatment market growth. For instance, in May 2019, Boehringer Ingelheim and Optimum Patient Care announced the creation of a new patient registry, APEX COPD, to better understand COPD and how it can be typically treated in primary care offices. Such initiatives by industry players are expected to boost global chronic obstructive pulmonary disease (COPD) treatment market over the forecast period. Moreover, pipeline for respiratory diseases and mainly COPD has several potential medications, which is expected to drive global chronic obstructive pulmonary disease (COPD) treatment market growth.

Key features of the study:

  • This report provides in-depth analysis of global chronic obstructive pulmonary disease (COPD) treatment market and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018–2026), considering 2017 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights into market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global chronic obstructive pulmonary disease (COPD) treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key companies covered as a part of this study include AstraZeneca Plc, Orion Corporation, Mylan N.V., Boehringer Ingelheim, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Novartis AG, Sunovion Pharmaceuticals, Inc., and CHIESI Farmaceutici SpA
  • Insights from this report would allow marketers and management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global chronic obstructive pulmonary disease (COPD) treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the global chronic obstructive pulmonary disease (COPD) treatment market

Detailed Segmentation:

  • Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Drug Class:
    • Bronchodilators
      • Beta 2-Agonists
      • Anticholinergics
      • Theophyllines
    • Phosphodiesterase Type 4 Inhibitors
    • Steroids
    • Others
  • Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Route of Administration:
    • Oral
    • Inhalation
  • Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Region:
    • North America
      • By Drug Class:
        • Bronchodilators
          • Beta 2-Agonists
          • Anticholinergics
          • Theophyllines
        • Phosphodiesterase Type 4 Inhibitors
        • Steroids
        • Others
      • By Route of Administration:
        • Oral
        • Inhalation
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.S.
        • Canada
    • Europe
      • By Drug Class:
        • Bronchodilators
          • Beta 2-Agonists
          • Anticholinergics
          • Theophyllines
        • Phosphodiesterase Type 4 Inhibitors
        • Steroids
        • Others
      • By Route of Administration:
        • Oral
        • Inhalation
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Class:
        • Bronchodilators
          • Beta 2-Agonists
          • Anticholinergics
          • Theophyllines
        • Phosphodiesterase Type 4 Inhibitors
        • Steroids
        • Others
      • By Route of Administration:
        • Oral
        • Inhalation
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • By Drug Class:
        • Bronchodilators
          • Beta 2-Agonists
          • Anticholinergics
          • Theophyllines
        • Phosphodiesterase Type 4 Inhibitors
        • Steroids
        • Others
      • By Route of Administration:
        • Oral
        • Inhalation
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • By Drug Class:
        • Bronchodilators
          • Beta 2-Agonists
          • Anticholinergics
          • Theophyllines
        • Phosphodiesterase Type 4 Inhibitors
        • Steroids
        • Others
      • By Route of Administration:
        • Oral
        • Inhalation
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Class:
        • Bronchodilators
          • Beta 2-Agonists
          • Anticholinergics
          • Theophyllines
        • Phosphodiesterase Type 4 Inhibitors
        • Steroids
        • Others
      • By Route of Administration:
        • Oral
        • Inhalation
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Region:
        • Central Africa
        • South Africa
        • North Africa
  • Company Profiles
    • AstraZeneca Plc*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • Orion Corporation
    • Mylan N.V.
    • Boehringer Ingelheim
    • Teva Pharmaceutical Industries Ltd.
    • GlaxoSmithKline plc
    • Novartis AG
    • Sunovion Pharmaceuticals, Inc.
    • CHIESI Farmaceutici SpA

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Class
      • Market Snippet, By Route of Administration
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Regulatory Scenario
    • Key Highlights
    • Research and Development Collaboration, Mergers, and Acquisitions
    • PEST Analysis
    • Pipeline Analysis
    • Epidemiology
  4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Drug Class, 2016–2026 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2017 and 2026 (%)
      • Y-o-Y Growth Analysis, 2018–2026
      • Segment Trends
    • Bronchodilators
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
        • Beta 2-Agonists
        • Anticholinergics
        • Theophyllines
    • Phosphodiesterase Type 4 Inhibitors
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
    • Steroids
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
  5. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Route of Administration, 2016–2026 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2017 and 2026 (%)
      • Y-o-Y Growth Analysis, 2018–2026
      • Segment Trends
    • Oral
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
    • Inhalation
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
  6. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Distribution Channel, 2016–2026 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2017 and 2026 (%)
      • Y-o-Y Growth Analysis, 2018–2026
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2026, (US$ Mn)
  7. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Regions, 2016–2026 (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2017 and 2026 (%)
      • Y-o-Y Growth Analysis, For Regions, 2018–2026
    • North America
      • Market Size and Forecast, By Drug Class, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2026 (US$ Mn)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Drug Class, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2026 (US$ Mn)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Class, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2026 (US$ Mn)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of APAC
    • Latin America
      • Market Size and Forecast, By Drug Class, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2026 (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Africa
      • Market Size and Forecast, By Drug Class, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2016–2026 (US$ Mn)
        • Central Africa
        • South Africa
        • North Africa
    • Middle East
      • Market Size and Forecast, By Drug Class, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Route of Administration, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016–2026 (US$ Mn)
      • Market Size and Forecast, By Country, 2016–2026 (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
  8. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
      • AstraZeneca Plc
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Orion Corporation
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Mylan N.V.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Boehringer Ingelheim
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Teva Pharmaceutical Industries Ltd.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • GlaxoSmithKline plc
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Novartis AG
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Sunovion Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • CHIESI Farmaceutici SpA
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
  9. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 26 market data tables and 32 figures on "Chronic Obstructive Pulmonary Disease (COPD) Treatment Market - Global forecast to 2026”.

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.